PRIVETERRA ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On February 14, 2023, AEON Biopharma, Inc. ("AEON") filed on this Current Report on Form 8-K stating that AEON issued a press release announcing that AEON will host a key opinion leader webinar on the past, present, and potential future treatments for migraine using botulinum toxin on Friday, February 24, 2023 at 11:00 a.m. Eastern Time (the "Webinar").

On February 24, 2023, AEON published the final presentation from the Webinar. A copy of the final presentation is furnished hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of PMGM under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1.

Item 9.01  Financial Statements and Exhibits.



(d) Exhibits



                                       2





Exhibit
  No.                                      Description

  99.1       Final Presentation, dated February 24, 2023
104        Cover Page Interactive Data File (embedded within the Inline XBRL document)


                                       3

© Edgar Online, source Glimpses